Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office (USPTO) has issued two US Patents directed towards biotechnology firm Ocata Therapeutics' Hemangio-derived Mesenchymal Cells (HMCs).
Subscribe to our email newsletter
The company’s HMC technology introduces a new era of cell therapy for ophthalmic, autoimmune and inflammatory diseases.
According to the company, this development allows the generation of a potentially unlimited supply of potent HMCs from renewable pluripotent stem cell sources.
Ocata chief scientific officer and co-inventor on the patents Dr Robert Lanza said: "HMCs have the potential to deliver greater therapeutic results than traditional mesenchymal stem cell therapies that have been the focus of clinical development for the past decade."
Apart from the HMC formulations, the issued patents also protect the manufacture of HMCs as well as the therapeutic use of these cells to treat ophthalmic, autoimmune and inflammatory diseases.
Ocata president and CEO Dr Paul Wotton said: "The unique and differentiating characteristics of our proprietary HMCs gives Ocata a distinct new platform to develop ophthalmic products, such as for treatment of non-infectious uveitis and inflammatory diseases of the retina.
"In addition to our ophthalmic uses, this platform now gives Ocata the ability to carve out the non-ophthalmic uses and to potentially partner this Restorative Immunology platform for the treatment of devastating autoimmune diseases, such as Lupus and Crohn’s Disease."
Ocata’s most advanced products are currently in clinical trials designed to treat Stargardt’s macular degeneration, dry age-related macular degeneration and myopic macular degeneration.